{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:49:29Z","timestamp":1794642569782,"version":"4.9.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Relapse of malignancy after allogeneic hematopoietic cell transplantation (allo-HCT) remains a therapeutic challenge. Blockade of the CTLA4 molecule can effectively augment antitumor immunity mediated by autologous effector T cells. We have assessed the safety and preliminary efficacy of a neutralizing, human anti-CTLA4 monoclonal antibody, ipilimumab, in stimulating the graft-versus-malignancy (GVM) effect after allo-HCT. Twenty-nine patients with malignancies that were recurrent or progressive after allo-HCT, received ipilimumab as a single infusion at dose cohorts between 0.1 and 3.0 mg\/kg. Dose-limiting toxicity was not encountered, and ipilimumab did not induce graft-versus-host disease (GVHD) or graft rejection. Organ-specific immune adverse events (IAE) were seen in 4 patients (grade 3 arthritis, grade 2 hyperthyroidism, recurrent grade 4 pneumonitis). Three patients with lymphoid malignancy developed objective disease responses following ipilimumab: complete remission (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mantle cell lymphoma. At the 3.0 mg\/kg dose, active serum concentrations of ipilimumab were maintained for more than 30 days after a single infusion. Ipilimumab, as administered in this clinical trial, does not induce or exacerbate clinical GVHD, but may cause organ-specific IAE and regression of malignancy. This study is registered at http:\/\/clinicaltrials.gov under NCI protocol ID P6082.<\/jats:p>","DOI":"10.1182\/blood-2008-07-168468","type":"journal-article","created":{"date-parts":[[2008,10,31]],"date-time":"2008-10-31T01:23:00Z","timestamp":1225416180000},"page":"1581-1588","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":319,"title":["CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation"],"prefix":"10.1182","volume":"113","author":[{"given":"Asad","family":"Bashey","sequence":"first","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla;"},{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Medina","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Corringham","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mildred","family":"Pasek","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Carrier","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vrooman","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israel","family":"Lowy","sequence":"additional","affiliation":[{"name":"Medarex, Bloomsbury, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence E.","family":"Morris","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Kent","family":"Holland","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Mason","sequence":"additional","affiliation":[{"name":"BMT, Scripps Clinic, La Jolla, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin P.","family":"Alyea","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Ball","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplantation, University of California, San Diego Moores Cancer Center, La Jolla;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111802545798200_B1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-4613-1261-1_12","article-title":"Treatment of relapse after allogeneic bone marrow transplantation.","volume":"84","author":"Giralt","year":"1996","journal-title":"Cancer Treat Res"},{"key":"2019111802545798200_B2","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1182\/blood-2007-03-078592","article-title":"Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.","volume":"110","author":"Kahl","year":"2007","journal-title":"Blood"},{"key":"2019111802545798200_B3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.19.1.225","article-title":"Complexities of CD28\/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.","volume":"19","author":"Salomon","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"2019111802545798200_B4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","article-title":"Checkpoint blockade in cancer immunotherapy.","volume":"90","author":"Korman","year":"2006","journal-title":"Adv Immunol"},{"key":"2019111802545798200_B5","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"2019111802545798200_B6","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade [see comments].","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"2019111802545798200_B7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","article-title":"Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.","volume":"190","author":"van Elsas","year":"1999","journal-title":"J Exp Med"},{"key":"2019111802545798200_B8","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111802545798200_B9","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4.","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111802545798200_B10","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study.","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2019111802545798200_B11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111802545798200_B12","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111802545798200_B13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/07357900701522315","article-title":"The role of the CTLA4 blockade in the treatment of malignant melanoma.","volume":"25","author":"Cranmer","year":"2007","journal-title":"Cancer Invest"},{"key":"2019111802545798200_B14","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111802545798200_B15","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111802545798200_B16","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"2019111802545798200_B17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"2019111802545798200_B18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/1078-0432.CCR-06-1974","article-title":"A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.","volume":"13","author":"O'Mahony","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2019111802545798200_B19","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111802545798200_B20","first-page":"1","article-title":"The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases.","volume":"8","author":"Saenger","year":"2008","journal-title":"Cancer Immun"},{"key":"2019111802545798200_B21","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.4049\/jimmunol.162.11.6368","article-title":"Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.","volume":"162","author":"Blazar","year":"1999","journal-title":"J Immunol"},{"key":"2019111802545798200_B22","author":"Investigator Brochure for Ipilimumab","year":"2007"},{"key":"2019111802545798200_B23","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.2741\/2411","article-title":"Can graft-versus-leukemia reactivity be dissociated from graft-versus-host disease?","volume":"12","author":"Sprangers","year":"2007","journal-title":"Front Biosci"},{"key":"2019111802545798200_B24","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease.","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/7\/1581\/1313766\/zh800709001581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/7\/1581\/1313766\/zh800709001581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T20:56:09Z","timestamp":1684616169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/7\/1581\/26009\/CTLA4-blockade-with-ipilimumab-to-treat-relapse-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,12]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,2,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-07-168468","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,12]]}}}